anmelden
Novartis Aktie
135,36
EUR
-0,80
EUR
-0,59
%
126,84
CHF
-0,58
CHF
-0,46
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 249,33 Mrd. EUR
KGV 18,30 Div. Rendite 3,38%WKN 904278
ISIN CH0012005267
Symbol NVSEF
AI Analyse
Werbung
Novartis Aktie Analyse
| 09.09.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 05.09.19 | Novartis Underweight | Barclays Capital | |
| 28.08.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 29.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 24.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 19.07.19 | Novartis Underweight | Barclays Capital | |
| 16.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 05.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 04.06.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 30.05.19 | Novartis Underweight | Morgan Stanley | |
| 29.05.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 24.05.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 09.05.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 06.05.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 25.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 24.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 10.04.19 | Novartis Underweight | Barclays Capital | |
| 10.04.19 | Novartis Underweight | Morgan Stanley | |
| 08.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 08.04.19 | Novartis Underweight | Barclays Capital | |
| 03.04.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 26.02.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 01.02.19 | Novartis Underweight | Barclays Capital | |
| 01.02.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 29.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 16.01.19 | Novartis Underweight | Barclays Capital | |
| 16.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 08.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 02.01.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 10.12.18 | Novartis Underweight | Barclays Capital | |
| 07.12.18 | Novartis Underweight | Barclays Capital | |
| 25.06.18 | Novartis Underweight | Barclays Capital | |
| 18.06.18 | Novartis Underweight | Barclays Capital | |
| 22.05.18 | Novartis Underweight | Barclays Capital | |
| 20.04.18 | Novartis Underperform | Credit Suisse Group | |
| 20.04.18 | Novartis Underweight | Barclays Capital | |
| 11.04.18 | Novartis Underweight | Barclays Capital | |
| 10.04.18 | Novartis Underperform | Credit Suisse Group | |
| 20.02.18 | Novartis Underweight | Barclays Capital | |
| 25.01.18 | Novartis Underweight | Barclays Capital | |
| 24.01.18 | Novartis Underperform | Credit Suisse Group | |
| 06.12.17 | Novartis Underperform | Merrill Lynch & Co., Inc. | |
| 25.10.17 | Novartis Underweight | Barclays Capital | |
| 05.07.17 | Novartis Underperform | Credit Suisse Group | |
| 06.06.17 | Novartis Underweight | Morgan Stanley | |
| 02.06.17 | Novartis Underweight | Barclays Capital | |
| 12.05.17 | Novartis Underweight | Morgan Stanley | |
| 26.04.17 | Novartis Underweight | Morgan Stanley | |
Werbung
Werbung
